Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Caldera Therapeutics will merge with Synlogic as part of a strategic acquisition aimed at enhancing drug development for inflammatory conditions. This merger is expected to provide financial support necessary for continued research and development. Synlogic, previously seeking strategic alternatives, hopes to benefit from Caldera's recent success and funding efforts.
Company Information
Company
Caldera Therapeutics
Location
Cambridge, Massachusetts, United States
About
Caldera Therapeutics is a clinical stage biotechnology company developing CLD-423, a first-in-class bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. The company aims to advance innovative biologics in IBD and has a senior leadership team with extensive experience in this field. Caldera has raised significant funding from renowned biotech investors to support its development programs.
Cambridge